Comparative Pharmacology

Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus HEPATAMINE 8.

Peer-Reviewed Evidence

Differential Analysis

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs HEPATAMINE 8%

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

Amino Acid Solution

Category C

HEPATAMINE 8%

Amino Acid Solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.

HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.

Clinical Dosing

Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.

Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.

Direct Interaction

None Documented